Application of semaphore Sema3A and pharmaceutical composition of semaphore Sema3A in treatment of thoracic aortic aneurysm
By constructing a systemic overexpression mouse model of Sema3A and using Sema3A recombinant protein, the problem of high trauma and high risk of thoracic aortic aneurysm treatment in the prior art was solved, effectively inhibiting and pathological improvement of thoracic aortic aneurysm was achieved, and the patient provided that the patient had a good inhibition and pathological improvement of thoracic aortic aneurysm was provided. New therapeutic targets and drug intervention methods have been developed.
Patent Information
- Application Number
- CN202411078919.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art has problems of high traumatic and high risk in the treatment of thoracic aortic aneurysms, and lacks understanding of pathogenesis and therapeutic targets, resulting in limited treatment methods.
Sema3A was used as a therapeutic target, and a systemic overexpression mouse model of Sema3A was constructed through CRISPR/Cas9 technology, and the Sema3A recombinant protein was used for treatment to inhibit the occurrence and development of thoracic aortic aneurysm.
By observing the results of Sema3A overexpressing mice and control groups, it was found that Sema3A can significantly reduce the occurrence and development of thoracic aortic aneurysm, reduce the incidence and mortality of dissection, improve the pathological morphology of the aorta, and provide a potential therapeutic target Points and drug intervention methods.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an application of a semaphorin Sema3A and a pharmaceutical composition thereof for treating thoracic aortic aneurysm. Background Art
[0002] Thoracic aortic aneurysm (TAA) refers to an expanded aneurysm (with a diameter greater than 1.5 times that of a normal artery) formed in the aorta above the diaphragm. The tearing of the inner wall of the thoracic aorta causes the separation of the aortic media and adventitia to form a thoracic aortic dissection, which can be complicated by TAA or occur alone.
[0003] In a human study, the presence of angiogenesis in the outer two-thirds of the medial layer of the aorta in aneurysmal aortas was significantly increased compared with that in healthy subjects.
[34] During the angiogenesis process, the newly formed endothelial cells of the aortic wall express intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). These two factors are also chemokines, which can further promote the infiltration of inflammatory cells and aggravate the inflammatory response. It can be seen that angiogenesis and inflammatory response promote each other, destroy the integrity of the vascular wall, cause vascular homeostasis imbalance and adverse remodeling, and then promote the formation and progression of TAA.
[0004] As mentioned above, TAA also found a significant increase in vasa vasorum in the aorta wall, and they are present at the junction of the media and adventitia, which is where the dissection occurs.
[38] The study found that inflammation in the arterial wall without angiogenesis is not enough to cause TAAD, indicating that the angiogenesis of the media layer is closely related to the occurrence of TAAD.
[38] In addition, a recent study showed that in syndromic thoracic aortic aneurysm (Marfan syndrome), exome sequencing identified genetic variants in genes involved in regulating angiogenesis.
[39] Therefore, we speculate that targeted inhibition of angiogenesis may effectively prevent the formation and development of TAA and reduce the incidence and mortality of dissection.
[0005] Angiogenesis is a series of complex biological processes regulated by pro-angiogenic and anti-angiogenic factors. The identification, interaction and physiological and pathological mechanisms of these factors have not yet been fully elucidated. Among these factors, VEGF is the strongest stimulator of angiogenesis. It regulates angiogenesis by binding to its receptor VEGFR2 and has been widely studied in physiology and various diseases.
[41] Antiangiogenic agents targeting VEGF or its receptors can inhibit the progression of AAA [42,43] In addition, studies have found that inhibiting VEGF also has a protective effect in TAA [40,44] At present, anti-angiogenic therapeutic drugs targeting VEGF, such as bevacizumab, ranibizumab, and sorafenib, have been used in clinical combination therapy for tumors.
[45] However, these drugs have side effects on the cardiovascular system, especially drug-induced hypertension, which is very common in clinical practice, limiting their application in cardiovascular diseases.
[46] Therefore, it is urgent to find other factors that regulate angiogenesis.
[0006] Sema3A is a member of the semaphorin family of brain signal proteins. It is a soluble secretory protein that exerts biological functions by binding to its receptors Plexins A and NRP1.
[53] Sema3A was initially studied extensively in the nervous system, and was found to inhibit the growth of nerve axons and induce the collapse of growth cones of specific neurons. Subsequently, it was discovered that Sema3A is also involved in the biological processes of multiple other systems in the body, such as angiogenesis, immune regulation, ECM remodeling, and tumorigenesis.
[54] Miao et al. first discovered that Sema3A can inhibit the migration of porcine aortic endothelial cells and prevent vascular sprouting by acting on NRP1, thus playing an anti-angiogenic role.
[55] Acevedo et al. found that Sema3A can inhibit VEGF-mediated angiogenesis
[56] Casazza et al. found in a tumor model that systemic overexpression of Sema3A has the effect of anti-angiogenesis and inhibiting tumor metastasis.
[57] In the cardiovascular system, Sema3A regulates angiogenesis by inhibiting integrin activity. Yu et al. found that intravitreal injection of Sema3A reduced neovascularization and abnormal vascular growth in an oxygen-induced retinopathy model.
[58] Adi et al. found that administration of Sema3A recombinant protein can reduce inflammation and angiogenesis in bronchial asthma.
[59] The above studies show that Sema3A has the effect of inhibiting angiogenesis and is involved in the progression of various diseases.
[0007] Thoracic aortic aneurysm usually has no obvious symptoms until dissection or rupture occurs. It is a serious life-threatening disease. Once a thoracic aortic aneurysm dissection or rupture occurs, the mortality rate is as high as over 90%. In my country, there are approximately 39,000 patients with aortic dissection as of 2021, which places a heavy economic burden. Existing drugs such as beta-blockers, angiotensin receptor antagonists, and TGF-β neutralizing antibodies can only maintain the mortality rate at around 50% after the onset of symptoms. Currently, the most effective treatment for various types of thoracic aortic aneurysms is open surgery or endovascular repair, but these methods are highly invasive and risky, and can only reduce the mortality rate by 30%. An important reason for the limited treatment methods is that little is known about its pathogenesis and even therapeutic targets. Therefore, it is urgent to explore the pathogenesis of thoracic aortic aneurysm and develop drugs that can delay the progression of TAA. Summary of the invention
[0008] The purpose of the present invention is to overcome the problems of high trauma and high risk in the prior art and to effectively inhibit the occurrence and development of thoracic aortic aneurysm.
[0009] In order to achieve the above-mentioned invention object, the technical solution adopted by the present invention is as follows:
[0010] Application of semaphorin Sema3A as an animal model target or therapeutic drug target for thoracic aortic aneurysm.
[0011] The application of semaphorin Sema3A is to use the preparation with increased expression level of Sema3A in the preparation of drugs for treating thoracic aortic aneurysm.
[0012] Application of semaphorin Sema3A, using Sema3A as a target, constructing mice with systemic overexpression of Sema3A, and replicating the thoracic aortic aneurysm model. The specific method is as follows:
[0013] 1) Construction of mice with systemic overexpression of Sema3A
[0014] Using CRISPR / Cas9 [clustered regularly interspaced short palindromicrepeats (CRISPR) / CRISPR associated (Cas) 9] technology, the corresponding expression frame was inserted by homologous recombination, and the target gene was induced to express and regulate through the Cre-LoxP system to construct a mouse model of conditional overexpression of Sema3a gene. After the model was successfully established, the Sema3a gene conditional knock-in mice were mated with UBC-CreER (systemic Cre) mice to obtain the systemic overexpression of Sema3a (i.e., Sema3a / Cre-ERTM) mice.
[0015] 2) Identification of mice with systemic overexpression of Sema3A
[0016] The tails of the genotyped mice were taken and the genotypes were identified by enzyme digestion and polymerase chain reaction. At the same time, the aortic tissues of the mice were collected to detect the transcription and protein levels of Sema3A to confirm that Sema3A was successfully overexpressed.
[0017] 3) Replication of thoracic aortic aneurysm model
[0018] Wild-type and Sema3A systemically overexpressing mice weighing 10 g were given BAPN (β-aminopropionitrile monofumarate) dissolved in sterile drinking water at a dose of 1.0 g / kg / day for 28 days, while the control group was given normal drinking water for 28 days.
[0019] A pharmaceutical composition for treating thoracic aortic aneurysm, wherein the effective ingredients thereof include a preparation for increasing the expression amount of Sema3A.
[0020] Optionally, the preparation for increasing the expression level of Sema3A is a recombinant protein of Sema3A.
[0021] Optionally, the preparation for increasing the expression level of Sema3A is a cell supernatant preparation overexpressing Sema3A.
[0022] Beneficial effects of the present invention:
[0023] The present invention observed the changes in the gross morphology of the thoracic aorta, the incidence of mouse dissection, the mortality rate, the diameter of the thoracic aorta, and pathological morphology of Sema3A-overexpressing mice and mice of the same litter after administration of BAPN or normal drinking water, and found that compared with the control group, the occurrence and development of thoracic aortic aneurysms were significantly reduced in mice with systemic overexpression of Sema3A after BAPN induction. And by observing the changes in the dialogue between aortic cells by Sema3A, the mechanism of action of Sema3A in thoracic aortic aneurysms was further elucidated, and thus the possibility of Sema3A as a therapeutic target for thoracic aortic aneurysms was determined. Furthermore, the present invention can effectively inhibit the occurrence and development of thoracic aortic aneurysms by intraperitoneally injecting the recombinant protein of Sema3A in a mouse model of thoracic aortic aneurysm, indicating that Sema3A can be used as a therapeutic target for the treatment of thoracic aortic aneurysms. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Schematic diagram of the western blot detection results of Sema3A in the aorta of human thoracic aortic aneurysm / dissection and the control group.
[0025] Figure 2Schematic diagram of the immunohistochemical detection results of Sema3A in the aorta of human thoracic aortic aneurysm / dissection and the control group.
[0026] Figure 3 Schematic diagram of the results of Sema3A transcription level detection in the aorta of mouse thoracic aortic aneurysm and control group.
[0027] Figure 4 Schematic diagram of the western blot detection results of Sema3A in the aorta of mouse thoracic aortic aneurysm and control group.
[0028] Figure 5 Schematic diagram of the immunohistochemical detection results of Sema3A in the aorta of mouse thoracic aortic aneurysm and control group.
[0029] Figure 6 Schematic diagram of the results of detecting the expression level of Sema3A in the aorta of mice with systemic overexpression of Sema3A.
[0030] Figure 7 Schematic diagram of the gross morphology of the aorta after BAPN induction in mice with systemic Sema3A overexpression compared with littermate control mice.
[0031] Figure 8 Schematic diagram of the pathological morphology of the aorta after BAPN induction in mice with systemic Sema3A overexpression compared with littermate control mice.
[0032] Fig. 9 Schematic diagram of the results of thoracic aorta diameter in mice with systemic Sema3A overexpression compared with littermate control mice after BAPN induction.
[0033] Fig.10 Schematic diagram of the results of dissection incidence in mice after BAPN induction in mice with systemic overexpression of Sema3A compared with littermate control mice.
[0034] Fig.11 Schematic diagram of the mouse mortality after BAPN induction in mice with systemic overexpression of Sema3A compared with littermate control mice.
[0035] Fig.12 Schematic diagram of the results of immunohistochemical detection of MMP2 / 9 in the aorta of mice after BAPN induction in mice with systemic overexpression of Sema3A compared with littermate control mice.
[0036] Fig.13 Schematic diagram of the results of gelatin zymography detection of serum MMP2 / 9 in mice with systemic overexpression of Sema3A after BAPN induction compared with littermate control mice.
[0037] Fig.14Schematic diagram of the results of CD68 immunohistochemistry in the aorta of mice after BAPN induction in mice with systemic overexpression of Sema3A compared with littermate control mice.
[0038] Fig.15 Schematic diagram of the results of mRNA levels of inflammatory factors and chemokines in the aorta of mice after BAPN induction in mice with systemic overexpression of Sema3A compared with littermate control mice.
[0039] Fig.16 Graph showing the results of VEGF mRNA levels in the aorta of mice after BAPN induction in mice with systemic Sema3A overexpression compared with littermate control mice.
[0040] Fig.17 Schematic diagram of the results of CD31 immunohistochemistry in the aorta of mice after BAPN induction in mice with systemic Sema3A overexpression compared with littermate control mice.
[0041] Fig.18 Schematic diagram of the western blot results of matrix metalloproteinases MMP2 / 9 and CD31 in the aorta of mice after BAPN induction in mice with systemic overexpression of Sema3A compared with littermate control mice.
[0042] Fig.19 Schematic diagram of the results of Sema3A knockdown efficiency detection in vascular smooth muscle cells.
[0043] Fig. 20 Effect of knocking down Sema3A in vascular smooth muscle cells on endothelial cell proliferation.
[0044] Fig.21 Effect of knockdown of Sema3A in vascular smooth muscle cells on endothelial cell migration.
[0045] Fig. 22 Effect of knockdown of Sema3A in vascular smooth muscle cells on endothelial cell tube formation.
[0046] Fig.23 The effect of overexpression of Sema3A in vascular smooth muscle cells on endothelial cell proliferation.
[0047] Fig.24 The effect of overexpression of Sema3A in vascular smooth muscle cells on endothelial cell migration.
[0048] Fig.25 The effect of overexpression of Sema3A in vascular smooth muscle cells on endothelial cell tube formation.
[0049] Fig.26 Schematic diagram of the results of NRP1 knockdown efficiency detection in endothelial cells.
[0050] Fig. 27 Effect of Sema3A recombinant protein on endothelial cell proliferation after knockdown of NRP1 in endothelial cells.
[0051] Fig.28 Effect of Sema3A recombinant protein on endothelial cell migration after knockdown of NRP1 in endothelial cells.
[0052] Fig.29 Effect of Sema3A recombinant protein on endothelial cell tube formation after knockdown of NRP1 in endothelial cells.
[0053] Fig.30 This is the effect of Sema3A recombinant protein on the MAPK pathway of endothelial cells.
[0054] Fig.31 The effects of systemic Sema3A overexpression on the aortic ERK pathway in mice and littermate control mice after BAPN induction.
[0055] Fig.32 The effect of knocking down Sema3A in vascular smooth muscle cells and simultaneously administering the ERK inhibitor U1026 on the ERK phosphorylation level.
[0056] Fig.33 The effects of knocking down Sema3A in vascular smooth muscle cells and simultaneously administering the ERK inhibitor U1026 on endothelial cell tube formation.
[0057] Fig.34 Wild-type mice were intraperitoneally injected with Sema3A recombinant protein, and the level of Sema3A in mouse serum was detected.
[0058] Fig.35 Schematic diagram of the gross morphology of the mouse aorta after BAPN induction in wild-type mice following intraperitoneal injection of Sema3A recombinant protein.
[0059] Fig.36 Schematic diagram of the pathological morphology of the mouse aorta after BAPN induction in wild-type mice following intraperitoneal injection of Sema3A recombinant protein.
[0060] Fig.37 Schematic diagram of the results of dissection incidence in wild-type mice after intraperitoneal injection of Sema3A recombinant protein and BAPN induction.
[0061] Fig.38 Schematic diagram of the mortality results of wild-type mice after intraperitoneal injection of Sema3A recombinant protein induction of BAPN.
[0062] Fig.39 Schematic diagram of the results of MMP2 / 9 immunohistochemistry in the aorta of wild-type mice after intraperitoneal injection of Sema3A recombinant protein and BAPN induction.
[0063] Fig.40 Schematic diagram of the results of gelatin zymogram of serum MMP2 / 9 in wild-type mice after intraperitoneal injection of Sema3A recombinant protein and BAPN induction.
[0064] Fig.41 Schematic diagram of the results of CD68 immunohistochemistry in the aorta of wild-type mice after intraperitoneal injection of Sema3A recombinant protein and BAPN induction.
[0065] Fig.42 Schematic diagram of the results of inflammatory factors and chemokine mRNA in the aorta of wild-type mice after intraperitoneal injection of Sema3A recombinant protein induction of BAPN.
[0066] Fig.43 Schematic diagram of the results of VEGF mRNA in the mouse aorta after BAPN induction in wild-type mice after intraperitoneal injection of Sema3A recombinant protein.
[0067] Fig.44 Schematic diagram of the results of CD31 immunohistochemistry in the aorta of wild-type mice after intraperitoneal injection of Sema3A recombinant protein and BAPN induction.
[0068] Fig.45 Schematic diagram of the results of the phosphorylation levels of MMP2 / 9, CD31 and ERK in the aorta of wild-type mice after intraperitoneal injection of Sema3A recombinant protein induction of BAPN. DETAILED DESCRIPTION
[0069] The present invention is further described below in conjunction with specific implementation modes, but the protection scope of the present invention is not limited thereto.
[0070] Biological and chemical reagents and test instruments used in the following examples
[0071] 1. Experimental Animals
[0072] The present invention uses two strains of experimental animals, namely, Sema3A systemically overexpressed mice and wild-type C57BL / 6j mice. C57B / L6J male C57B / L6J wild (wild type, WT) mice were purchased from the Experimental Animal Center of Shanxi Medical University, and the animal certification number is SCXK (Jin) 2019-0004. The mice were all raised in the SPF-level animal room of the Key Laboratory of Cell Physiology of the Ministry of Education of Shanxi Medical University, with a normal diet and free drinking water. The control group drank normal sterile drinking water, and BAPN (1.0g / Kg / d) was added to the drinking water of the TAA group and dissolved in sterile drinking water. The experimental mice were all male and weighed 10g. All animal experiments were performed in accordance with the experimental procedures specified by the Experimental Animal Management Committee of Shanxi Medical University.
[0073] (1) Construction of mice with systemic overexpression of Sema3A
[0074] Using CRISPR / Cas9 [clustered regularly interspaced short palindromicrepeats (CRISPR) / CRISPR associated (Cas) 9] technology, the TH promoter-loxp-stop-loxp-Sema3a-IRES-GFP-WPRE-polyA expression frame was inserted into the Rosa26 gene locus through homologous recombination. The Cre-LoxP system was used to regulate the inducible expression of the target gene. Construction
[0075] Rosa26-(SA / pCAG)-loxpStop-loxp-cDNA-pA recombinant vector was used to obtain Sema3a gene conditional knock-in mice. The model was commissioned by Southern Model Organisms Technology Co., Ltd. for establishment. The protocol is shown in Figure 1 .
[0076] After the model was successfully established, the mice were crossed and bred in our laboratory.
[0077] Sema3a conditional knock-in mice were crossed with UBC-CreER (systemic Cre) mice to obtain mice that overexpressed Sema3a systemically (i.e., Sema3a / Cre-ER TM ) mice. UBC-CreER mice were purchased from Southern Model Organisms Technology Co., Ltd. The animal certification number is SCXK (Shanghai) 2019-0002.
[0078] 2. Experimental cells
[0079] (1) Mouse aortic primary smooth muscle cells were obtained by enzymatic digestion of mouse aorta.
[0080] (2) Human umbilical vein endothelial cells (HUVEC) were purchased from ATCC Cell Bank, USA.
[0081] 3. Main reagents, test kits and preparation methods are shown in Tables 1, 2 and 3.
[0082] Table 1 List of antibodies, reagents, and kits
[0083]
[0084]
[0085] Table 2 Separation gel preparation method
[0086]
[0087] Table 3 Separation gel preparation method
[0088]
[0089] 4. Experimental Animal Grouping
[0090] (1) Expression level of Sema3A in the aorta of wild-type mice
[0091] Sixteen wild-type mice were randomly divided into two groups, with 8 mice in each group: WT+normal drinking water group (WT+vehicle group) as the control group; WT+BAPN group as the experimental group.
[0092] (2) Effects of systemic Sema3a overexpression in mice on TAA formation and progression
[0093] Sema3a / Cre-ER TM and Cre-ER TM A total of 100 mice were divided into the following four groups: ①Cre-ER TM +vehicle group (n=25); ②Sema3a / Cre-ER TM +vehicle group (n=25); ③Cre-ER TM +BAPN group (n=25); ④Sema3a / Cre-ER TM +BAPN group (n=25).
[0094] (3) Observation on the therapeutic effect of mouse Sema3A recombinant protein (mRSema3A) on TAA
[0095] A total of 60 wild-type mice were divided into 3 groups: ①WT+vehicle+PBS group (n=20); ②WT+BAPN+PBS group (n=20); ③WT+BAPN+mRSema3A group (n=20). mRSema3A 25μg was dissolved in PBS, with a final concentration of 100μg / mL; starting from the 14th day of modeling, the experimental group mice were intraperitoneally injected with mRSema3A at a concentration of 6μg / mL, 20μL per day, for a total of 10 days. The control group was given PBS at the same dose and for the same time.
[0096] All experiments in the following embodiments were repeated at least 3 times, and all count data and measurement data were expressed as mean ± standard deviation (Mean ± SD). The comparison between two groups of measurement data was performed by group t test (conforming to normal distribution) or rank sum test (not conforming to normal distribution). For comparison of three or more groups, variance analysis was used. P < 0.05 was used as the standard for judging whether the difference was statistically significant. All data were statistically analyzed using Graphpad Prism 9.3.0 (San Diego, USA) software.
[0097] Example 1: Systemic overexpression of Sema3A in mice can reduce the occurrence and development of TAA
[0098] 1.1 Detection of Sema3A protein levels in aorta of human TAA / TAAD and control group:
[0099] (1) Experimental groups: The HTAA / TAAD group consisted of thoracic aortic disease tissue removed during surgical treatment of TAA / TAAD patients (n=10); the control group consisted of a small amount of ascending aorta tissue (without aneurysm) obtained during coronary heart disease bypass surgery in patients (hCTL group, n=10). Both the control group and the patients were male, Han nationality, with an average age of 50-62 years old, and both groups had no genetic diseases. All aortic specimens were obtained according to the protocol approved by Shanxi Medical University (No. 2023SJL34).
[0100] (2) Western blot experiment: Take vascular tissue and add tissue protein lysis buffer (i.e., add 10 μL of protease inhibitor and 10 μL of phosphatase inhibitor to 1 mL of lysis buffer), add magnetic beads, place the centrifuge tube in a low-temperature freezing grinder, grind twice at 60 Hz for 45 seconds, and collect the supernatant after centrifugation to obtain the extracted protein. The protein concentration was determined using a BCA kit, and the loading amount for each sample was 60 μg. Prepare separation gel and concentration gel according to Tables 2 and 3 for polyacrylamide gel (SDS-PAG) electrophoresis. After the electrophoresis, transfer the protein from the gel to the solid phase support PVDF membrane by wet transfer. After 2 hours of transfer, block with 5% skim milk at room temperature for 1 hour, incubate with anti-rabbit Sema3A antibody at 4°C overnight, and incubate with secondary antibody at room temperature for 1 hour the next day. Use the Bio-Rad chemiluminescence imaging system to collect images and analyze and measure the optical density value of the target band.
[0101] (3) Immunohistochemistry: Paraffin sections were dewaxed to water and antigen retrieval was performed with 1× citric acid solution. The sections were then washed three times with PBS for 5 minutes each time. Subsequent experiments were performed according to the instructions of the rabbit two-step kit, as follows: endogenous peroxidase blocker was added to the tissue, incubated at room temperature for 15 minutes, and washed three times with PBS for 3 minutes each time. Serum was added to the tissue for blocking for 30 minutes at room temperature. After drying, the primary antibody was added directly, and the slides were placed in a humidified box at 4°C overnight. The next day, the humidified box was taken out and equilibrated at room temperature for 30 minutes; washed three times with PBS for 3 minutes each time. Enzyme-labeled goat anti-rabbit / mouse IgG polymer was added, incubated at 37°C for 20 minutes; washed three times with PBS for 3 minutes each time. An appropriate amount of freshly prepared DAB color development solution was added. After color development, the slides were washed three times with PBS for 3 minutes each time. The cell nuclei were then stained. After staining, the slides were dehydrated in a gradient ethanol solution, transparentized with xylene, and mounted with a neutral resin. The sections were observed and imaged using a Nikon ECLIPSE Ni microscope at a 400x field of view, and the positive area or number of positive cells was counted using NIS-Element software.
[0102] (4) Experimental results
[0103] like Figure 1 As shown, the protein level of Sema3A in the aorta of TAA / TAAD patients was significantly reduced compared with that of the control population.
[0104] like Figure 2 As shown, the positive signal area of Sema3A in the thoracic aorta of human TAA / TAAD was significantly reduced compared with that of the control population.
[0105] 1.2 Detection of Sema3A transcription and protein levels in aorta of TAA mice and control mice
[0106] (1) Extraction of total RNA from vascular tissue
[0107] The whole aorta tissue of the mouse was placed in an enzyme-free centrifuge tube, 1 mL of Trizol and sterilized magnetic beads were added, and the centrifuge tube was placed in a low-temperature freezing grinder and ground twice at 60 Hz for 45 seconds. Centrifuge at 12000 rpm and 4°C for 15 min; the supernatant was aspirated into the centrifuge tube, and then 200 μL of chloroform was added, and the tube was inverted vigorously, and the tube was allowed to stand at room temperature for 10 min, and then centrifuged at 12000 rpm and 4°C for 15 min. The upper water layer was aspirated into a new centrifuge tube. An equal volume of isopropanol was added to the supernatant, and the tube was gently mixed, and centrifuged at 12000 rpm and 4°C for 15 min. The supernatant was discarded, and the precipitate was left. 1000 μL of 75% ethanol prepared with DEPC water was added, and the tube was centrifuged at 12000 rpm and 4°C for 10 min. The supernatant was aspirated and discarded, and 10 μL of DEPC water was added to dissolve the supernatant. The DNA / RNA concentration meter was turned on to determine the RNA concentration. Its integrity was detected by 1% agarose gel electrophoresis.
[0108] (2) Reverse transcription of mRNA to cDNA: Follow the instructions of the reverse transcription kit.
[0109] (3) Real-time quantitative PCR (RT-qPCR) was performed according to the instructions of the kit. The experiment was performed using a QuantStudio3 real-time quantitative PCR instrument. A reliable CT value curve was obtained after analyzing the melting curve. β-actin was used as the internal reference gene, and the relative expression of the target gene = 2 (internal reference gene CT value - target gene CT value). The RT-qPCR sequences used in the experiment are shown in Table 4.
[0110] Table 4 RT-qPCR primer sequences
[0111]
[0112] The protein level of Sema3A in mouse aorta was detected by western blot and immunohistochemistry. The experimental methods are as described above.
[0113] (4) Experimental results:
[0114] like Figure 3 As shown, drinking BAPN-containing water resulted in a significant decrease in the mRNA level of Sema3A in the aorta of TAA mice compared with drinking normal water.
[0115] like Figure 4 and Figure 5 As shown, the protein level of Sema3A in BAPN-induced TAA aorta was significantly decreased compared with the control group.
[0116] The above findings, namely, that Sema3A levels in the aorta of human and mouse TAA are reduced, suggest that Sema3A is closely related to the occurrence and development of TAA.
[0117] 1.3 Detection of Sema3A expression level in the aorta of mice with systemic overexpression of Sema3A RT-qPCR and western blot methods were used to detect the expression level of Sema3A in the aorta of littermate control mice and mice with systemic overexpression of Sema3A.
[0118] Experimental results: Figure 6 As shown, with Cre-ER TM Compared with control mice, Sema3a / Cre-ER TM The mRNA and protein levels of Sema3A in mouse aorta were significantly increased, indicating that the overexpression in mice was successful.
[0119] 1.4 Effect of systemic Sema3A overexpression in mice on the development of thoracic aortic aneurysms
[0120] (1) Hematoxylin-eosin (HE) staining
[0121] Paraffin sections were dewaxed to water (100% ethanol, 95% ethanol, 80% ethanol, each 5 minutes), hematoxylin stained for 5 minutes, washed with tap water to remove floating color, hydrochloric acid alcohol differentiation solution for 2 seconds, tap water to blue for 1-2 minutes, and distilled water washed for 30 seconds. Eosin staining for 7 minutes, tap water rinse for 1 minute. Dehydration, transparent, sealing and image collection; ethanol gradient immersion (80% ethanol, 95% ethanol, 100% ethanol, each 3 minutes), xylene transparent, neutral resin sealing. The sections were observed and images were collected under a Nikon ECLIPSE Ni microscope.
[0122] (2) Dyeing of elastic fibers
[0123] Paraffin sections were dewaxed to water. One drop (100 μL) of Lugol iodine solution was added to the tissue for 5 min, and the sections were washed in tap water for 30 sec. One drop of sodium thiosulfate was added and incubated for 5 min, and the sections were rinsed in tap water for 5 min, and then washed in 70% ethanol for 30 sec. One drop of aldehyde fuchsin dye was added and dyed for 10 min, and the sections were rinsed twice in 70% ethanol, and then washed in tap water for 1 sec. One drop of orange G dye was added and dyed for 1 sec, and then washed in tap water for 30 sec. The sections were washed in gradient ethanol (80% ethanol, 95% ethanol, and 100% ethanol for 3 min each), and then transparentized in xylene and sealed with neutral resin. The sections were observed and photographed under a Nikon ECLIPSE Ni microscope.
[0124] (3) Ultrasound measurement of the thoracic aorta in mice with TAA
[0125] Use Vevo LAB small animal ultrasound to detect thoracic aortic aneurysms. After the mouse is anesthetized with isoflurane, the mouse testing platform is tilted to the left at an appropriate angle, the Ao Arch detection mode is selected, the probe direction is adjusted, and the probe is moved after obtaining the right ventricle image to obtain the long-axis section of each segment of the thoracic aorta and measure its inner diameter. Then adjust the angle of the examination platform, place the probe in the mouse's suprasternal fossa, and adjust the direction until the long-axis view of the ascending aorta is obtained. Measure the blood flow velocity at the mouse aortic valve orifice.
[0126] (4) Experimental results
[0127] like Figure 7 As shown, the thoracic aorta of the control mice formed tumors after BAPN induction, while no obvious tumors were found in the thoracic aorta of the mice with systemic overexpression of Sema3a after BAPN induction; the blood vessels of the mice with systemic overexpression of Sema3a and the control mice were normal after drinking normal water, and no tumors were formed.
[0128] like Figure 8 As shown, HE staining showed that the thoracic aorta wall of the control mice was significantly thickened after BAPN induction, while the vascular morphology of the mice with systemic overexpression of Sema3a after BAPN induction was close to that of the normal drinking water group. Elastic fiber staining showed that the vascular elastic fibers of the control mice were disordered, missing and formed dissection after BAPN induction, while the vascular elastic fibers of the mice with systemic overexpression of Sema3a after BAPN induction were neatly arranged and intact.
[0129] like Fig. 9 As shown, compared with drinking normal water, the inner diameter of the thoracic aorta of control mice increased significantly after BAPN induction, while the inner diameter of the aorta of mice with systemic overexpression of Sema3a did not show significant enlargement after BAPN induction.
[0130] like Fig.10 As shown, after BAPN induction, 12 out of 16 control mice developed dissection, while after BAPN induction, only 6 out of 21 mice in Sema3a systemically overexpressed mice developed dissection; the blood vessels of Sema3a systemically overexpressed mice and control mice in the same littermates were normal when drinking ordinary water, and no dissection was formed. Fig.11 As shown, the control mice in the same littermate died as early as 15 days after BAPN induction, and 9 out of 16 mice died; the Sema3a systemically overexpressed mice died as early as 25 days after BAPN induction, and only 3 out of 21 mice died; the Sema3a systemically overexpressed mice and the control mice in the same littermate all survived by drinking normal water.
[0131] 1.5 Effects of systemic Sema3A overexpression in mice on BAPN-induced aortic extracellular matrix degradation, inflammatory response, and vasorum angiogenesis
[0132] (1) Gelatin zymography experiment: The experiment was carried out according to the instructions of the gelatin zymography kit. The specific steps are as follows:
[0133] 1. Prepare SDS-PAG gel containing MMP substrate protein: The recommended separation gel concentration is 8%. Prepare SDS-PAG gel according to standard procedures.
[0134] 2. Sample preparation: Whole blood was collected from mouse eyeballs, and after standing at room temperature for 2 hours, it was centrifuged at 3000 rpm for 15 minutes, and the serum was drawn into a centrifuge tube. The serum samples were quantified using the BCA concentration determination method, and the loading amount of each sample was uniformly 60 μg.
[0135] 3. Low current constant current electrophoresis, each small gel current is 20mA / gel. The electrophoresis ends when bromophenol blue runs out of the front of the gel.
[0136] 4. Wash the gel with 10mL of 1×Buffer A, pour out Buffer A, add 10mL of 1×Buffer B, incubate at room temperature for 4h, pour out Buffer B, add Coomassie Brilliant Blue staining solution for 2h, and decolorize with decolorizing solution (prepared with glacial acetic acid: methanol: water = 7:5:88) until a transparent area appears on the gel. The unstained transparent area is the location of the MMP band. Scan the gel on a scanner, adjust the background display to grayscale display, and set it to black, and the MMP band is white.
[0137] 5. Total RNA was extracted from aortic tissue and converted into cDNA. RT-qPCR was used to detect the mRNA expression levels of IL-1β, TNF-α, MCP-1, VCAM-1, ICAM-1, VEGF, and IL-6 in the aorta. The RT-qPCR sequences used in the experiment are shown in Table 5.
[0138] Table 5 RT-qPCR primer sequences
[0139]
[0140] (2) Experimental results
[0141] like Fig.12 As shown in the figure, the positive signal areas of MMP2 and MMP9 in the littermate control mice after BAPN induction were significantly higher than those in the normal drinking water group; TM Compared with the +BAPN group, Sema3a / Cre-ER TM The positive areas of MMP2 and MMP9 in the thoracic aorta of mice in the +BAPN group were significantly reduced.
[0142] The activity of MMP2 / 9 was detected by gelatin zymography. Fig.13As shown in Figure 2, compared with the littermate control mice after BAPN induction, the serum MMP2 and MMP9 activities of the mice with systemic overexpression of Sema3A were significantly reduced after BAPN induction. Fig.14 As shown, Cre-ER TM The infiltration of macrophages in the thoracic aorta of mice in the +BAPN group was significantly increased and mainly concentrated in the adventitia of the blood vessels; TM There was only a very small amount of macrophage infiltration in the adventitia of the aorta of mice in the +BAPN group.
[0143] like Fig.15 As shown, with Cre-ER TM Compared with the +vehicle group, Cre-ER TM In the aorta tissue of mice in the +BAPN group, the mRNA expression of VCAM-1, ICAM-1, MCP-1, IL-1β, and TNF-α were significantly increased; TM Compared with the +BAPN group, Sema3a / Cre-ER TM The levels of inflammatory factors and chemokines in the aorta of mice in the +BAPN group were significantly reduced.
[0144] like Fig.16 The results show that the level of VEGF in the aorta of the control mice after BAPN induction was significantly higher than that of the mice drinking normal water; while after BAPN induction, the level of VEGF in the mice with systemic overexpression of Sema3a was significantly reduced compared with that of the control mice of the same littermate.
[0145] like Fig.17 As shown, the level of CD31 in the aorta of control mice after BAPN induction was significantly higher than that of mice drinking normal water; while after BAPN induction, the positive area of CD31 in mice with systemic overexpression of Sema3a was significantly reduced compared with that of the control mice of the same littermate.
[0146] like Fig.18 As shown, the protein levels of MMP9, MMP2, and CD31 in the aorta of mice with systemic overexpression of Sema3a were significantly reduced compared with those of littermate control mice.
[0147] 1.6 Sema3A derived from vascular smooth muscle cells acts on endothelial NRP1 receptors, downregulates the ERK pathway, and inhibits the proliferation, migration and tube formation of endothelial cells.
[0148] (1) Isolation and culture of primary VSMCs from mouse aorta
[0149] The mice were killed by cervical dislocation, and the whole body of the mice was disinfected by spraying 75% ethanol. The mice were fixed on the mouse board in the supine position, and the chest and abdominal cavities were cut open, and various organs and tissues in the cavity were removed to expose the entire aorta. In the clean bench, under the microscope, the mouse aorta was separated, and the blood vessels were moved to a culture dish containing collagenase II and digested at 37°C for 0.5h. The preparation of collagenase II was: 1mg collagenase II (374U / mg) was dissolved in 1mL of Hanks solution without calcium and magnesium. The vascular tissue was moved to a culture dish containing calcium and magnesium to terminate the digestion, and the vascular adventitia was completely peeled off under the microscope. The vascular tissue without the adventitia was placed in a mixed enzyme of collagenase II + elastase, and the vascular tissue was cut into small pieces and digested in a 37°C water bath for 0.5h. Preparation of mixed enzyme: 1 mg collagenase II (374 U / mg) and 0.5 mg elastase (6 U / mg) were dissolved in 1 mL of Hanks solution without calcium and magnesium. Add excess Hanks solution with calcium and magnesium to terminate digestion, gently blow with a pipette tip, transfer the cell suspension to a 15 mL centrifuge tube, centrifuge at 1000 rpm at room temperature for 5 minutes, resuspend the cells in 10% smooth muscle cell culture medium, and inoculate in a cell culture dish.
[0150] (2) Cultivation of HUVEC
[0151] HUVEC were purchased from ATCC Cell Bank in the United States. The cells were cultured in 10% endothelial cell culture medium at 37°C in an environment containing 5% CO2. Cells were subcultured when the cell density reached 80%-90%, and cells before P7 were used for experiments as much as possible.
[0152] (3) Cell gene silencing experiment
[0153] Centrifuge tubes containing siRNA powder at 1000rpm for 1min, gently open the lid, add the corresponding volume of DEPC water according to the concentration to prepare 20μM storage solution, then divide into centrifuge tubes and store at -80℃ for use. Cells are inoculated in six-well plates with a density of 30%-50% for siRNA treatment. Add 5μL siRNA to 250μL Opti-MEM medium and mix well. Add 5μL transfection reagent lipofectamine to 250μL Opti-MEM medium. TM3000, gently blow to mix evenly, and let stand at room temperature for 5 minutes. Gently mix the liquids in steps 3 and 4, and let stand at room temperature for 20 minutes. Add 500 μL of the transfection complex to the six-well cell plate to make the final siRNA concentration 50nM, and gently shake the cell plate to mix the liquid evenly. After 6 hours, replace with fresh complete culture medium. The siRNA sequences used in the experiment are shown in Table 6.
[0154] Table 6 Specific gene siRNA primer sequences
[0155]
[0156] (4) Scratch test
[0157] Use a marker pen to draw 5 horizontal lines on the back of the 6-well plate. After HUVEC digestion and resuspension, press 1×10 5 The number of cells / well was inoculated into a 6-well culture plate. Cultured overnight in a cell culture incubator. The next day, the 6-well culture plate was removed and scratched perpendicularly to the horizontal line on the back of the well plate with a 200μL pipette tip. The cells were rinsed with PBS to remove the scratched cells and serum-free culture medium containing different treatment factors was added. Photos were taken at 0h, 6h, 12h, and 24h. Image J software was used to count the cell scratch area. Cell migration rate = (initial scratch area - scratch area at a certain time) / initial scratch area.
[0158] (5) Transwell cell invasion assay
[0159] 1. Preparation of Transwell chamber: Dilute Matrigel with cell culture medium at a dilution ratio of 1:30, take 50 μL and add it to the transwell chamber, place it at 37°C, take it out after 30 minutes, and use a pipette to suck out the residual liquid in the chamber.
[0160] 2. Inoculation of cells: 8×10 4 The cells were seeded in transwell chambers, 600 μL of cell culture medium containing 10% serum and treatment factors were added to the lower chamber, and cultured in a cell culture incubator for 24 h.
[0161] 3. Staining: Take out the transwell chamber, discard the culture medium, wash twice with PBS, 3 minutes each time, gently wipe the cells on the upper surface of the chamber with a cotton swab, add 100 μL of 4% paraformaldehyde for fixation, add crystal violet for staining after 30 minutes, wash three times with PBS after 20 minutes, 3 minutes each time. Use Nikon ECLIPSE Ti2 microscope to observe the cells and take pictures and count.
[0162] (6) EdU cell proliferation assay
[0163] EdU is a thymidine analog that can be incorporated into the DNA double strand during DNA synthesis. The EdU proliferation assay is based on a "click" reaction, a copper-catalyzed atomic covalent reaction of azide and alkyne. Refer to the EdU kit instructions for the following method: 4 × 10 3 Cells were seeded in 96-well plates, and the stimulation cells were added the next day. After 24 hours, EdU working solution was added to each well to a final concentration of 20 μM, and incubated at 37°C for 2 hours. The culture medium was discarded, 50 μL of 4% paraformaldehyde was added, and the liquid was removed after 30 minutes. 50 μL of glycine solution was added and incubated at room temperature for 5 minutes. Subsequently, the cells were washed twice with 0.1 mL of 3% BSA, and the liquid was discarded. 0.1 mL of 0.5% Triton X-100 was added and incubated at room temperature for 20 minutes. The liquid was removed, 0.1 mL of 3% BSA was added, and the liquid was discarded. The Click-iT reaction mixture was prepared according to the instructions according to the required amount of the experiment, 0.1 mL was added to each well, and the cells were gently shaken to cover the liquid. Incubate at room temperature in the dark for 30 minutes. The liquid was discarded, 0.1 mL of 3% BSA was added, and the washing liquid was removed. 0.1 mL of PBS was added to wash, and the liquid was discarded. Prepare 1×Hoechst33342 solution to a final concentration of 5μg / mL. Add 0.1mL of 1×Hoechst33342 solution and incubate at room temperature in the dark for 30min. Discard the liquid, add 0.1mL of PBS to wash twice, and discard the liquid. Use Nikon ECLIPSE Ti2 microscope to take pictures and use ImageJ software to count the number of EdU positive cells.
[0164] (7) Endothelial cell tube formation experiment
[0165] The cell culture medium was replaced with 0.5% complete medium the night before and cultured overnight in a cell culture incubator. The matrix gel and pipette tip were pre-cooled at 4 degrees. The next day, the matrix gel was added to each well of the 96-well plate, 50 μL per well (the experiment was performed on ice throughout to prevent the matrix gel from preheating and solidifying), and incubated at 37°C for 30 minutes. The cells were digested and 0.25×10 5 The cells were inoculated in a 96-well plate covered with matrix gel, and the corresponding stimulating factors were added. The cells were photographed at 6h and 12h.
[0166] (8) Cell experiment grouping
[0167] 1. Sema3A was knocked down in vascular smooth muscle cells, and the supernatant was collected to treat endothelial cells to observe the effects on endothelial cell proliferation, migration and tube formation. The cell experiment groups were as follows:
[0168] ①AngII+Scramble siRNA supernatant transfection group (control group); ②AngII+siRNA1 supernatant transfection group; ③AngII+siRNA2 supernatant transfection group; ④AngII+siRNA3 supernatant transfection group.
[0169] 2. Vascular smooth muscle cells overexpressed Sema3A, and the supernatant was collected to treat endothelial cells to observe the effects on endothelial cell proliferation, migration and tube formation. The cell experiment groups were as follows:
[0170] ①AngII+Cre-ER TM Supernatant group (control group); ②AngII+Sema3a / Cre-ER TM Supernatant group (experimental group).
[0171] 3. After knocking down NRP1 in endothelial cells, the effects of Sema3A on the proliferation, migration and tube formation of endothelial cells were observed. The cells were grouped as follows:
[0172] ①Scramble siRNA+AngII+hRSema3A group (control group); ②NRP1 siRNA1+AngII+hRSema3A group (experimental group).
[0173] (9) Experimental results
[0174] like Fig.19 As shown, compared with the negative control, the mRNA levels of Sema3a were significantly reduced after transfection of three different Sema3a siRNA sequences, indicating that Sema3a knockdown was successful.
[0175] like Fig. 20 As shown in Figure 2, compared with the negative control group, the number of EdU-positive cells increased after HUVEC cells were treated with the supernatant of VSMCs transfected with three different Sema3a siRNAs. Fig.21 As shown in the figure, the longitudinal migration of cells was detected by transwell experiment. It can be seen that compared with the control group, the number of HUVEC cells migrating increased significantly after being treated with the supernatant of VSMC transfected with Sema3a siRNA2 and Sema3a siRNA3. The lateral migration of cells was detected by scratch experiment. It can be seen that compared with the Scramble siRNA supernatant group, the cell scratch healing rate was significantly increased after HUVEC cells were treated with the supernatant of VSMC transfected with 3 different Sema3a siRNAs, and it showed an increasing trend from 6h to 24h. Fig. 22As shown, compared with the Scramble siRNA supernatant group, after treatment with the supernatant of VSMC transfected with three different Sema3a siRNAs, the number of HUVEC cells formed tubes increased at 6 h, and the tubules in the control group were almost completely disintegrated at 12 h, but the HUVEC cells treated with the three different Sema3A siRNA supernatant groups still had some intact tubules.
[0176] Fig.23 Schematic diagram of the results of detecting the overexpression level of Sema3A in vascular smooth muscle cells (supplementary ELISA).
[0177] like Fig.24 As shown, compared with the control group, the number of EdU-positive cells in endothelial cells was significantly reduced when the supernatant of vascular smooth muscle cells overexpressing Sema3A was treated with endothelial cells.
[0178] like Fig.25 As shown, the scratch test results showed that compared with the control group, the endothelial cells were treated with the supernatant of vascular smooth muscle cells overexpressing Sema3A, and the endothelial cell scratch healing rate was significantly reduced at 12h and 24h. The Transwell experiment results showed that compared with the control group, the endothelial cells were treated with the supernatant of vascular smooth muscle cells overexpressing Sema3A, which reduced the number of endothelial cells migrating longitudinally.
[0179] like Fig.26 As shown, complete tubules were formed in the control group at 6 h, but after vascular smooth muscle cells overexpressed Sema3A to treat endothelial cells, there were almost no complete tubules in the endothelial cells at 6 h.
[0180] like Fig. 27 As shown, compared with the negative control group, the mRNA level of NRP1 was significantly reduced in HUVEC cells treated with three different NRP1 siRNAs.
[0181] like Fig.28 As shown, knockdown of NRP1 receptor and Sema3A in endothelial cells promoted the proliferation of endothelial cells compared with the control group.
[0182] like Fig.29 As shown, knockdown of NRP1 receptor and Sema3A in endothelial cells promoted the migration of endothelial cells compared with the control group.
[0183] like Fig.30 As shown, knockdown of NRP1 receptor and Sema3A in endothelial cells promoted endothelial cell tube formation compared with the control group.
[0184] like Fig.31As shown, compared with the control group, the ERK phosphorylation (p-ERK) level of HUVECs treated with hRSema3A was significantly decreased, while the phosphorylation (p-JNK and p-p38) levels of other members of the MAPK pathway, JNK and p38, did not change significantly.
[0185] like Fig.32 As shown, the p-ERK level in the aorta of mice with systemic overexpression of Sema3a was significantly decreased after BAPN induction compared with that of the littermate control mice induced by BAPN.
[0186] like Fig.33 As shown, compared with the control group, the cell culture supernatant after knockdown of smooth muscle cell Sema3A can upregulate the p-ERK level of endothelial cells; after treatment with U0126, the level of p-ERK is reduced, indicating that U0126 can effectively inhibit the ERK signaling pathway.
[0187] like Fig.34 As shown, compared with the control group, the cell culture supernatant after knockdown of smooth muscle cell Sema3A also promoted the formation of EC tubules; while after administration of U0126, the formation of tubules was inhibited.
[0188] Based on the above experimental results, this example uses Sema3A systemically overexpressed mice to replicate a thoracic aortic aneurysm model, and found that the incidence of dissection in Sema3a systemically overexpressed mice after BAPN induction was significantly reduced, and the survival rate was significantly improved; the inner diameter of the thoracic aorta and the thickness of the thoracic aorta were significantly reduced, and the disordered arrangement and rupture of elastic fibers were significantly improved. At the same time, the two pathological characteristics of TAA, namely the degradation of the extracellular matrix and the inflammatory response, were also improved in mice with systemic overexpression of Sema3a. It should be noted that systemic overexpression of Sema3a inhibited the regeneration of aortic vasculogenesis, suggesting that the protective effect of Sema3A on TAA may be related to its inhibition of aortic vasculogenesis. Further in vitro cell experiments found that the mechanism by which Sema3A inhibits angiogenesis is that Sema3A derived from vascular smooth muscle cells acts on the endothelial NRP1 receptor, downregulates the ERK signaling pathway, and inhibits the proliferation, migration and tube formation of endothelial cells. Example 1 provides the application of semaphorin Sema3A, which has the value of being a potential therapeutic target for animal models of thoracic aortic aneurysm.
[0189] Example 2 Therapeutic effect of Sema3A recombinant protein on thoracic aortic aneurysm
[0190] In this part of the experiment, wild-type mice were intraperitoneally injected with mouse Sema3A recombinant protein, and molecular biology and pathological methods were used to observe the gross morphology and pathological morphology of the mouse aorta, statistically analyze the incidence and mortality of dissection, and observe the degradation of extracellular matrix, inflammatory response and angiogenesis during the development of thoracic aortic aneurysm, in order to evaluate the therapeutic effect of Sema3A recombinant protein in thoracic aortic aneurysm.
[0191] (1) Preparation of Sema3A recombinant protein
[0192] The mouse Sema3a sequence was inserted into an appropriate vector using genetic engineering technology, and then the recombinant vector was transferred into a specific host cell. The host cell was induced to express the target protein under appropriate conditions, and the pure recombinant protein was extracted from the host cell using separation and purification technology. After the protein was obtained, the binding activity was tested to ensure its efficacy. Mouse Sema3A recombinant protein was purchased from Shanghai Zeye Biotechnology Co., Ltd.
[0193] (2) Experimental results
[0194] like Fig.35 As shown, a tumor was formed in the ascending aorta in the BAPN+PBS group, while no obvious tumor was observed in any segment of the thoracic aorta after administration of mRSema3A.
[0195] like Fig.36 As shown in the figure, HE staining results showed that the thoracic aorta wall of mice in the BAPN+PBS group was significantly thickened, while the vascular wall of the BAPN+mRSema3A group was not significantly thickened, and the morphology was similar to that of the normal drinking water group. Elastic fiber staining results showed that the vascular elastic fibers in the BAPN+PBS group were disordered and broken, while the vascular elastic fibers in the BAPN+mRSema3A group were neatly arranged and intact.
[0196] like Fig.37 As shown, 9 out of 14 mice in the BAPN+PBS group developed dissection, while only 3 out of 16 mice in the BAPN+mRSema3A group developed dissection; the blood vessels of the group drinking normal water were normal and no dissection formed.
[0197] like Fig.38 As shown, the earliest death of mice in the BAPN+PBS group occurred on the 13th day, and 7 out of 14 mice died; while only 2 mice in the BAPN+mRSema3A group died on the 14th day, and the rest all survived.
[0198] like Fig.39 As shown, compared with the group given normal drinking water, the protein levels of MMP9 and MMP2 in the thoracic aorta of mice were significantly increased after BAPN induction; while after administration of mRSema3A, both MMP9 and MMP2 in the thoracic aorta were significantly decreased.
[0199] like Fig.40 As shown, the activity of serum MMP2 / 9 was also significantly reduced after intraperitoneal injection of mRSema3A compared with the BAPN+PBS group.
[0200] like Fig.41 As shown, compared with the administration of normal drinking water, the number of macrophages in the thoracic aorta adventitial membrane of mice increased significantly after BAPN-induced TAA; while after intraperitoneal injection of mRSema3A, the infiltration of macrophages in the thoracic aorta adventitial membrane was significantly reduced.
[0201] like Fig.42 As shown, compared with drinking ordinary water, the mRNA levels of MCP-1, VCAM-1, ICAM-1, IL-1β, TNF-α and IL-6 in aortic tissue were significantly increased after BAPN induction, while the transcription levels of the above factors were significantly decreased after administration of mRSema3A.
[0202] like Fig.43 As shown, compared with drinking normal water, the mRNA level of VEGF in the aorta was significantly increased after BAPN induction, while the mRNA level of VEGF in the aorta was significantly decreased after intraperitoneal injection of mRSema3A.
[0203] like Fig.44 As shown, compared with drinking normal water, the CD31-positive cells in the thoracic aorta of mice increased significantly after BAPN induction; while after administration of mRSema3A, the CD31-positive cells in the thoracic aorta decreased significantly.
[0204] like Fig.45 As shown in the figure, compared with drinking normal water, the protein levels of MMP2 / 9 and CD31 in the aorta were significantly increased after BAPN induction, while the protein levels of MMP2 / 9 and CD31 were decreased after intraperitoneal injection of mRSema3A. In addition, administration of exogenous mRSema3A also reduced the level of p-ERK in the mouse aorta.
[0205] Based on the above experimental results, Example 2 found that intraperitoneal injection of recombinant Sema3A can reduce the incidence of dissection in TAA mice and improve the survival rate; significantly improve the pathological progression of aortic aneurysm (manifested by the fact that the gross morphology of the aorta in the mRSema3A group is close to normal, and the elastic fibers of the vascular wall are neatly arranged and intact); reduce aortic ECM degradation, reduce inflammatory response, inhibit angiogenesis; and downregulate the protein level of aortic p-ERK. It can be seen that exogenous Sema3A recombinant protein can effectively intervene in the process of TAA and reduce the incidence of TAAD. Exogenous Sema3A recombinant protein may be developed into a drug for the treatment of TAA.
[0206] The technical solutions provided by the embodiments of the present invention are introduced in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the embodiments of the present invention. The description of the above embodiments is only applicable to help understand the principles of the embodiments of the present invention. At the same time, for those skilled in the art, according to the embodiments of the present invention, there will be changes in the specific implementation methods and application scopes. In summary, the content of this specification should not be understood as limiting the present invention.
Claims
1. Application of semaphorin Sema3A, characterized in that: As an animal model target or therapeutic drug target for thoracic aortic aneurysm.
2. The use of the semaphorin Sema3A according to claim 1, characterized in that: The preparation that increases the expression level of Sema3A is used to prepare drugs for treating thoracic aortic aneurysms.
3. The use of the semaphorin Sema3A according to claim 1, characterized in that: Sema3A was used as the target to construct a mouse model of systemic overexpression of Sema3A and to replicate the thoracic aortic aneurysm model. The specific method is as follows: 1) Construction of mice with systemic overexpression of Sema3A Using CRISPR / Cas9 technology, the corresponding expression frame was inserted through homologous recombination, and the expression of the target gene was regulated by the Cre-LoxP system to construct a mouse model of conditional overexpression of the Sema3a gene. After that, the Sema3a gene conditional knock-in mice were mated with UBC-CreER mice to obtain a strain of mice with systemic overexpression of Sema3a. 2) Identification of mice with systemic overexpression of Sema3A The tails of the genotyped mice were taken and the genotypes were identified by enzyme digestion and polymerase chain reaction. At the same time, the aortic tissues of the mice were collected to detect the transcription and protein levels of Sema3A to confirm the successful overexpression of Sema3A. 3) Replication of thoracic aortic aneurysm model Wild-type and Sema3A systemically overexpressing mice weighing 10 g were given β-aminopropionitrile fumarate BAPN dissolved in sterile drinking water at a dose of 1.0 g / Kg / day for 28 days, while the control group was given normal drinking water for 28 days.
4. A pharmaceutical composition for treating thoracic aortic aneurysm, characterized in that: Its active ingredients include a preparation that increases the expression level of Sema3A.
5. The pharmaceutical composition according to claim 4, characterized in that The preparation for increasing the expression amount of Sema3A is a recombinant protein of Sema3A.
6. The pharmaceutical composition according to claim 4, characterized in that The preparation for increasing the expression level of Sema3A is a cell supernatant preparation that overexpresses Sema3A.
